A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds
DOI: https://doi.org/10.2147/dddt.s450499
IF: 4.3188
2024-05-08
Drug Design Development and Therapy
Abstract:Muhammad Shahid Nazir, 1 Matloob Ahmad, 1 Sana Aslam, 2 Ayesha Rafiq, 1 Sami A Al-Hussain, 3 Magdi EA Zaki 3 1 Department of Chemistry, Government College University, Faisalabad, Pakistan; 2 Department of Chemistry, Government College Women University, Faisalabad, Pakistan; 3 Department of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia Correspondence: Matloob Ahmad; Magdi EA Zaki, Email ; The Coronavirus disease 2019 (COVID-19) pandemic is one of the most considerable health problems across the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the major causative agent of COVID-19. The severe symptoms of this deadly disease include shortness of breath, fever, cough, loss of smell, and a broad spectrum of other health issues such as diarrhea, pneumonia, bronchitis, septic shock, and multiple organ failure. Currently, there are no medications available for coronavirus patients, except symptom-relieving drugs. Therefore, SARS-CoV-2 requires the development of effective drugs and specific treatments. Heterocycles are important constituents of more than 85% of the physiologically active pharmaceutical drugs on the market now. Several FDA-approved drugs have been reported including molnupiravir, remdesivir, ritonavir, oseltamivir, favipiravir, chloroquine, and hydroxychloroquine for the cure of COVID-19. In this study, we discuss potent anti-SARS-CoV-2 heterocyclic compounds that have been synthesized over the past few years. These compounds included; indole, piperidine, pyrazine, pyrimidine, pyrrole, piperazine, quinazoline, oxazole, quinoline, isoxazole, thiazole, quinoxaline, pyrazole, azafluorene, imidazole, thiadiazole, triazole, coumarin, chromene, and benzodioxole. Both in vitro and in silico studies were performed to determine the potential of these heterocyclic compounds in the fight against various SARS-CoV-2 proteins. Keywords: COVID-19, SARS-CoV-2, heterocyclic nucleus, in vitro, in silico, molecular docking studies Graphical Coronavirus disease 2019 (COVID-19 or 2019-nCoV), a fatal respiratory illness, was first identified in late December 2019 in Wuhan, China, and spread rapidly across 200 countries around the world. 1 On March 11, 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic. 2 The WHO renamed the virus as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on February 20, 2020. 3 The Beta, Delta, and Omicron variants started to emerge in Africa in May 2020, in India by October 2020, and in various other regions in November 2021, causing many concerns worldwide. 4 The coronavirus, is highly contagious in the air, can transmit from one person to another through respiratory aerosols and droplets. 5,6 The breathing problems caused by COVID-19 can be fatal in some cases, resulting in a global public health emergency. 7 Common symptoms of the disease include; shortness of breath (19%), fever (88%), loss of smell (15–30%), and cough (68%), as well as diarrhea, pneumonia, bronchitis, septic shock, multiple organ failure, and acute respiratory distress syndrome. 8,9 The causative agent of COVID-19 is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 10 The SARS-CoV-2 is an enveloped, crown-shaped, single-stranded positive RNA virus that belongs to the genus β-coronavirus , subgenus Sarbecovirus , and family Coronaviridae. 11 The SARS-CoV-2 is the seventh type of human coronavirus (HCoVs) after SARS-CoV, HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43, and middle east respiratory syndrome (MERS-CoV). 12 The SARS-CoV-2, MERS-CoV, and SARS-CoV viruses cause severe acute respiratory infections, whereas the HCoV-HKU1, HCoV-229E, HCoV-OC43, and HCoV-NL63 viruses affect with milder symptoms. The genome sequence of SARS-CoV-2 is 88% similarity to SARS-like bat coronaviruses (bat-SL-CoVZXC21 and bat-SL-CoVZC45), about 79% similar to SARS-CoV, and has about 50% similarity to MERS-CoV. 13 The SARS-CoV-2 genome contains approximately 30,000 nucleotides in the sequence of 5′-replicase-S-E-M-N-3′. 14 The SARS-CoV-2 genome has two major overlapping open reading frames (ORF1a/b) that encode four structural proteins (sps): spike (S), envelope (E), membrane (M), and nucleocapsid (N), and nonstructural proteins (nsps), as well as accessory factors. 15 The nsps1–nsps16 are encoded proteins that are responsible for viral transcription and replication, such as papain-like protease (PL pro ; nsp 3 ), RNA-dependent RNA polymerase (RdRp; nsp 12 ), 3-chymotrypsin-like protease (3CL pro ; nsp 5 ), also calle -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal